Evicenter
P&T meetings

Emcitate (tiratricol)

MCT8 deficiency

Last updated
78 sources

Product information and disease descriptionProduct descriptionProduct information

Product comparison

2 evidence topics · 3 sources

Comparison with diiodothyropropionic acid: published management recommendations

“TRIAC and DITPA are TH analogues that bypass MCT8-dependent transport and activate thyroid hormone receptors (THRs). TRIAC has a high affinity for THR β, reduces serum T3 levels, and ameliorates peripheral thyrotoxic manifestations, with the strongest clinical evidence supporting its use. DITPA similarly lowers serum T3 levels but is supported by less consistent clinical data. For both agents, the extent of improvement in neurological outcomes remains uncertain” (opens the source at this quote in a new tab)

“TRIAC is associated with substantially higher costs than conventional TH preparations, requiring individualized cost-benefit evaluation within different healthcare systems.” (opens the source at this quote in a new tab)

Comparison with the reference product Téatrois

“The main body of efficacy evidence is acquired in the TRIAC I in which the reference product “Téatrois, 0.350 mg IR tablet” approved in France during the period from 1974 to 2020 was used. This formulation is now discontinued.” (opens the source at this quote in a new tab)

“Reportedly, the only difference between Téatrois /Emcitate-DEV and Emcitate FCP with regards to excipients is the tablet filler, where calcium hydrogen phosphate dihydrate is replaced by calcium hydrogen phosphate to improve tablet properties.” (opens the source at this quote in a new tab)

“The MCT8-2023-5 study established bioequivalence between the two formulations Emcitate-DEV and Emcitate FCP for both Cmax and the various measures of AUC considered, with all 95% confidence intervals within the acceptance region of [0.80, 1.25].” (opens the source at this quote in a new tab)